Kenyataan Media Kementerian Kesihatan Malaysia : peluasan rawatan antiviral Paxlovid ke fasiliti kesihatan swasta dan penggunaan ubat antibodi Evusheld untuk mencegah Covid-19

Simple item page
dc.contributor.authorMalaysia, Kementerian Kesihatan
dc.date2022
dc.date.accessioned2025-10-13T07:52:07Z
dc.date.issued2022-06-08
dc.descriptionThis item is made available on Ministry of Health Malaysia, Covid-19 homepage at http://covid-19.moh.gov.my/en_US
dc.identifier.citation3 p.en_US
dc.identifier.urihttps://dspace.unimap.edu.my/handle/123456789/13616
dc.identifier.urlhttp://covid-19.moh.gov.my/
dc.language.isomsen_US
dc.publisherKementerian Kesihatan Malaysia (KKM)en_US
dc.subject.otherCovid 19en_US
dc.subject.otherCovid 19 -- Malaysiaen_US
dc.subject.otherStatus terkinien_US
dc.subject.otherSituasi semasaen_US
dc.subject.otherCoronavirus 2019 (Covid-19)en_US
dc.subject.otherKenyataan Akhbar -- Kementerian Kesihatan Malaysiaen_US
dc.titleKenyataan Media Kementerian Kesihatan Malaysia : peluasan rawatan antiviral Paxlovid ke fasiliti kesihatan swasta dan penggunaan ubat antibodi Evusheld untuk mencegah Covid-19en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kenyataan Media Kementerian Kesihatan Malaysia - peluasan rawatan antiviral Paxlovid ke fasiliti kesihatan swasta dan penggunaan ubat antibodi Evusheld untuk mencegah Covid-19.pdf
Size:
71.12 KB
Format:
Adobe Portable Document Format
Description:
Access is limited to UniMAP community.
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Press Release, Speeches and Addresses